HERON THERAPEUTICS, INC. /DE/

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

HRTX$0.37+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders' Equity

Series A · Accumulated
Convertible · Additional · Other · Total
Common Stock · Preferred Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Shares · Amount · Capital · (Loss) Income · Deficit · Equity
Balance as of December 31, 2025	188,314	$1,883	70	$1,050	$1,951,185	$4		$(1,939,789)	$14,333
Issuance of common stock under equity incentive plan	262	3	—	—	(54)	—		—	(51)
Stock-based compensation expense	—	—	—	—	2,976	—		—	2,976
Net loss	—	—	—	—	—	—		(8,111)	(8,111)
Net unrealized loss on short-term investments	—	—	—	—	—	(10)		—	(10)
Comprehensive loss							(8,121)
Balance as of March 31, 2026 (unaudited)	188,576	1,886	70	1,050	1,954,107	(6)		(1,947,900)	9,137
Issuance of common stock under equity incentive plan	654	7	—	—	(150)	—		—	(143)
Issuance of common stock under the employee stock purchase plan	229	2	—	—	223	—		—	225
Stock-based compensation expense	—	—	—	—	3,178	—		—	3,178
Net loss and comprehensive loss	—	—	—	—	—	—		(5,489)	(5,489)
Balance as of June 30, 2026 (unaudited)	189,459	1,895	70	1,050	1,957,358	(6)		(1,953,389)	6,908
Issuance of common stock under equity incentive plan	453	5	—	—	(73)	—		—	(68)
Stock-based compensation expense	—	—	—	—	3,083	—		—	3,083
Net loss	—	—	—	—	—	—		(5,006)	(5,006)
Net unrealized loss on short-term investments	—	—	—	—	—	(1)		—	(1)
Comprehensive loss							(5,007)
Balance as of September 30, 2026 (unaudited)	189,912	$1,900	70	$1,050	$1,960,368	$(7)		$(1,958,395)	$4,916

Series A · Accumulated
Convertible · Additional · Other · Total
Common Stock · Preferred Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Shares · Amount · Capital · (Loss) Income · Deficit · Equity
Balance as of December 31, 2024	152,128	$1,521	—	$—	$1,884,409	$13		$(1,919,594)	$(33,651)
Issuance of common stock under equity incentive plan	299	3	—	—	61	—		—	64
Stock-based compensation expense	—	—	—	—	2,511	—		—	2,511
Net income	—	—	—	—	—	—		2,635	2,635
Net unrealized loss on short-term investments	—	—	—	—	—	(12)		—	(12)
Comprehensive income							2,623
Balance as of March 31, 2025 (unaudited)	152,427	1,524	—	—	1,886,981	1		(1,916,959)	(28,453)
Issuance of common stock under equity incentive plan	438	5	—	—	189	—		—	194
Issuance of common stock under the employee stock purchase plan	388	4	—	—	583	—		—	587
Stock-based compensation expense	—	—	—	—	2,797	—		—	2,797
Net loss	—	—	—	—	—	—		(2,381)	(2,381)
Net unrealized loss on short-term investments	—	—	—	—	—	(2)		—	(2)
Comprehensive loss							(2,383)
Balance as of June 30, 2025 (unaudited)	153,253	1,533	—	—	1,890,550	(1)		(1,919,340)	(27,258)
Issuance of common stock under equity incentive plan	179	1	—	—	(52)	—		—	(51)
Issuance of common stock in settlement of 2026 Convertible Notes	16,667	167	—	—	30,500	—		—	30,667
Issuance of common stock in a private placement equity offering	13,225	132	—	—	18,175	—		—	18,307
Issuance of Series A convertible preferred stock in a private placement equity offering	—	—	524	7,862	—	—		—	7,862
Stock-based compensation expense	—	—	—	—	2,852	—		—	2,852
Net loss	—	—	—	—	—	—		(17,495)	(17,495)
Net unrealized gain on short-term investments	—	—	—	—	—	1		—	1
Comprehensive loss							(17,494)
Balance as of September 30, 2025 (unaudited)	183,324	$1,833	524	$7,862	$1,942,025	$—		$(1,936,835)	$14,885

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.